Merck & Co (MRK) Earnings Date & Reports

Merck reported worldwide sales of $16.3 billion for Q1 2026, a 5% increase from $15.5 billion in Q1 2025 (3% excluding foreign exchange impacts). This topped analyst consensus of approximately $15.9 billion, driven by oncology and newer products. Human health sales rose 5% to $14.3 billion, while animal health grew 13% to $1.8 billion.

GAAP net loss was $4.2 billion, or EPS loss of $1.72, compared to net income of $5.1 billion and EPS of $2.01 last year. Non-GAAP EPS loss was $1.28 versus $2.22, reflecting a $9.0 billion ($3.62 per share) charge for the Cidara Therapeutics acquisition recorded in R&D expenses (GAAP) and adjusted out in non-GAAP. Excluding the charge, underlying profitability improved on sales momentum.

Standouts included Keytruda/Keytruda Qlex at $8.0 billion (+12%), Winrevair at $525 million (+88%), offset by Gardasil/Gardasil 9 declines to $1.1 billion (-19%) due to softer demand in China and Japan. Non-GAAP gross margin was 81.9%, slightly down, with operating expenses elevated by acquisition costs.

Merck narrowed and raised its full-year 2026 outlook: sales $65.8-$67.0 billion (prior $65.5-$67.0 billion), non-GAAP EPS $5.04-$5.16 (prior $5.00-$5.15), incorporating ~1 point positive FX and Cidara charge, excluding pending Terns acquisition.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your stock analysis workflow.

Market Reaction and Investor Sentiment

Merck shares initially rose nearly 5% in pre-market trading on the sales beat and upbeat guidance but pared gains, closing down 0.5% at $110.35 on April 30. Investors appeared to focus on underlying strength in Keytruda and Winrevair, balanced against acquisition-related charges and Gardasil weakness. Sentiment remains cautiously optimistic, with attention on pipeline progress amid Keytruda's looming patent cliff.

Forward Outlook and Key Factors to Monitor

Merck's raised 2026 guidance signals confidence in core growth drivers, but investors should track execution amid pipeline catalysts. Upcoming PDUFA (FDA Prescription Drug User Fee Act) dates include ifinatamab deruxtecan for small cell lung cancer (Oct. 10) and Welireg combinations for renal cell carcinoma (June 19, Oct. 4). The Terns Pharmaceuticals acquisition, expected to close in May, will add TERN-701 for chronic myeloid leukemia (CML), though it carries ~$2.35 per share charge.

Keytruda demand remains robust across indications, but biosimilar risks post-2028 loom large. Winrevair's U.S. and international uptake, alongside Capvaxive's retail momentum, offer diversification. Gardasil recovery hinges on China/Japan demand and U.S. CDC timing. Monitor R&D spend post-Cidara/Verona integrations, gross margins amid FX volatility, and animal health trends.

Broader factors include generic erosion on Januvia/Janumet, oncology competition, and M&A (mergers and acquisitions) impacts on debt and EPS. Phase 3 readouts ahead will shape long-term prospects.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations